Piers C. Emson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Piers C. Emson has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Richard Lewis Maxwell Faull
Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand
3 shared publications Rebecca E. Colebrooke
Laboratory of Molecular Neuroscience, The Babraham Institute, Cambridge, CB2 4AT, UK
2 shared publicationsWilliam R.J. Whitaker
Department of Neurobiology, The Babraham Institute, Babraham, Cambridge CB2 4AT, United Kingdom
2 shared publications- Adam Zaidel
Gonda Brain Research Center, Bar-Ilan University
1 shared publication - Adriana Galvan
Emory National Primate Research Center, Emory University
1 shared publication Andrew J. Powell
Molecular Pharmacology Unit, GlaxoWellcome Medicines Research Centre, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
1 shared publication
Latest Publications
- 1 January 2010
- Published by Elsevier
Contributors
- 13 November 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 24 (9) , 2622-2630
Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease
Dopamine cytotoxicity is thought to contribute towards the selective loss of substantia nigra pars compacta dopamine neurons and disease progression in Parkinson's disease. However, the long‐term toxicity of dopamine in vivo has not previously been established. The vesicular monoamine transporter 2 (VMAT2) sequesters monoamines into synaptic vesicles, a process that, in addition to being important in normal transmission, may also act to keep intracellular levels of monoamine neurotransmitters below potentially toxic thresholds. The homozygous VMAT2‐hypomorphic mouse has an insertion in the VMAT2 gene (Slc18a2). Consequently, VMAT2‐deficient mice (VD–/–) have an ∼ 95% reduction in VMAT2 expression and an equivalent level of dopamine depletion in the striatum which results in moderate motor impairment. Here, we show that L‐DOPA induces locomotor hyperactivity in VD–/– mice and reverses the deficit in motor coordination and balance as tested with the rotarod. We report that evidence for cytosolic accumulation of dopamine in substantia nigra neurons in these mice is two‐fold: firstly, there is reduced phosphorylation of tyrosine hydroxylase at the residue associated with catechol feedback inhibition; and, secondly, there are increased rates of dopamine turnover at 6, 12 and 24 months of age. These animals exhibit a progressive decline in striatal monoamine levels and rotarod performance with increasing age. However, despite these data, there was no loss of nigral dopamine neurons as estimated by quantification of tyrosine hydroxylase‐immunoreactive cells in the substantia nigra pars compacta of old VD–/– mice (24‐month‐old), implying that these age‐dependent manifestations may be due to senescence alone.
- 13 November 2006
- Published by Wiley in European Journal of Neuroscience
- Vol. 24 (9) , 2622-2630
Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease
Dopamine cytotoxicity is thought to contribute towards the selective loss of substantia nigra pars compacta dopamine neurons and disease progression in Parkinson's disease. However, the long‐term toxicity of dopamine in vivo has not previously been established. The vesicular monoamine transporter 2 (VMAT2) sequesters monoamines into synaptic vesicles, a process that, in addition to being important in normal transmission, may also act to keep intracellular levels of monoamine neurotransmitters below potentially toxic thresholds. The homozygous VMAT2‐hypomorphic mouse has an insertion in the VMAT2 gene (Slc18a2). Consequently, VMAT2‐deficient mice (VD–/–) have an ∼ 95% reduction in VMAT2 expression and an equivalent level of dopamine depletion in the striatum which results in moderate motor impairment. Here, we show that L‐DOPA induces locomotor hyperactivity in VD–/– mice and reverses the deficit in motor coordination and balance as tested with the rotarod. We report that evidence for cytosolic accumulation of dopamine in substantia nigra neurons in these mice is two‐fold: firstly, there is reduced phosphorylation of tyrosine hydroxylase at the residue associated with catechol feedback inhibition; and, secondly, there are increased rates of dopamine turnover at 6, 12 and 24 months of age. These animals exhibit a progressive decline in striatal monoamine levels and rotarod performance with increasing age. However, despite these data, there was no loss of nigral dopamine neurons as estimated by quantification of tyrosine hydroxylase‐immunoreactive cells in the substantia nigra pars compacta of old VD–/– mice (24‐month‐old), implying that these age‐dependent manifestations may be due to senescence alone.
- 2 October 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 100 (2) , 368-381
Expression and localization of Parkinson's disease‐associated leucine‐rich repeat kinase 2 in the mouse brain
Mutations in the gene encoding leucine‐rich repeat kinase 2 (LRRK2) have been identified as the cause of familial Parkinson's disease (PD) at the PARK8 locus. To begin to understand the physiological role of LRRK2 and its involvement in PD, we have investigated the distribution of LRRK2 mRNA and protein in the adult mouse brain. In situ hybridization studies indicate sites of mRNA expression throughout the mouse brain, with highest levels of expression detected in forebrain regions, including the cerebral cortex and striatum, intermediate levels observed in the hippocampus and cerebellum, and low levels in the thalamus, hypothalamus and substantia nigra. Immunohistochemical studies demonstrate localization of LRRK2 protein to neurones in the cerebral cortex and striatum, and to a variety of interneuronal subtypes in these regions. Furthermore, expression of LRRK2 mRNA in the striatum of VMAT2‐deficient mice is unaltered relative to wild‐type littermate controls despite extensive dopamine depletion in this mouse model of parkinsonism. Collectively, our results demonstrate that LRRK2 is present in anatomical brain regions of direct relevance to the pathogenesis of PD, including the nigrostriatal dopaminergic pathway, in addition to other regions unrelated to PD pathology, and is likely to play an important role in the normal function of telencephalic forebrain neurones and other neuronal populations.
- 2 October 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 100 (2) , 368-381
Expression and localization of Parkinson's disease‐associated leucine‐rich repeat kinase 2 in the mouse brain
Mutations in the gene encoding leucine‐rich repeat kinase 2 (LRRK2) have been identified as the cause of familial Parkinson's disease (PD) at the PARK8 locus. To begin to understand the physiological role of LRRK2 and its involvement in PD, we have investigated the distribution of LRRK2 mRNA and protein in the adult mouse brain. In situ hybridization studies indicate sites of mRNA expression throughout the mouse brain, with highest levels of expression detected in forebrain regions, including the cerebral cortex and striatum, intermediate levels observed in the hippocampus and cerebellum, and low levels in the thalamus, hypothalamus and substantia nigra. Immunohistochemical studies demonstrate localization of LRRK2 protein to neurones in the cerebral cortex and striatum, and to a variety of interneuronal subtypes in these regions. Furthermore, expression of LRRK2 mRNA in the striatum of VMAT2‐deficient mice is unaltered relative to wild‐type littermate controls despite extensive dopamine depletion in this mouse model of parkinsonism. Collectively, our results demonstrate that LRRK2 is present in anatomical brain regions of direct relevance to the pathogenesis of PD, including the nigrostriatal dopaminergic pathway, in addition to other regions unrelated to PD pathology, and is likely to play an important role in the normal function of telencephalic forebrain neurones and other neuronal populations.
- 19 June 2000
- Published by Wiley in Journal of Comparative Neurology
- Vol. 422 (1) , 123-139
Distribution of voltage-gated sodium channel ?-subunit and ?-subunit mRNAs in human hippocampal formation, cortex, and cerebellum
The distribution of mRNAs encoding voltage-gated sodium channel α subunits (I, II, III, and VI) and β subunits (β1 and β2) was studied in selected regions of the human brain by Northern blot and in situ hybridisation experiments. Northern blot analysis showed that all regions studied exhibited heterogenous expression of sodium channel transcripts. In situ hybridisation experiments confirmed these findings and revealed a predominantly neuronal distribution. In the parahippocampal gyrus, subtypes II and VI and the β-subunit mRNAs exhibited robust expression in the granule cells of the dentate gyrus and pyramidal cell layer of the hippocampus. Subtypes I and III showed moderate expression in granule cells and low expression in the pyramidal cell layer. Distinct expression patterns were also observed in the cortical layers of the middle frontal gyrus and in the entorhinal cortex. In particular, all subtypes exhibited higher levels of expression in cortical layers III, V, and VI compared with layers I and II. All subtypes were expressed in the granular layer of the cerebellum, whereas specific expression of subtypes I, VI, β1, and β2 mRNAs was observed in Purkinje cells. Subtypes I, VI, and β1 mRNAs were expressed, at varying levels, in the pyramidal cells of the deep cerebellar nuclei. These data indicate that, as in rat, human brain sodium channel mRNAs have a distinct regional distribution, with individual cell types expressing different compliments of sodium channels. The differential distribution of sodium channel subtypes suggest that they have distinct roles that are likely to be of paramount importance in maintaining the functional heterogeneity of central nervous system neurons. J. Comp. Neurol. 422:123–139, 2000.
- 19 June 2000
- Published by Wiley in Journal of Comparative Neurology
- Vol. 422 (1) , 123-139
Distribution of voltage-gated sodium channel ?-subunit and ?-subunit mRNAs in human hippocampal formation, cortex, and cerebellum
The distribution of mRNAs encoding voltage-gated sodium channel α subunits (I, II, III, and VI) and β subunits (β1 and β2) was studied in selected regions of the human brain by Northern blot and in situ hybridisation experiments. Northern blot analysis showed that all regions studied exhibited heterogenous expression of sodium channel transcripts. In situ hybridisation experiments confirmed these findings and revealed a predominantly neuronal distribution. In the parahippocampal gyrus, subtypes II and VI and the β-subunit mRNAs exhibited robust expression in the granule cells of the dentate gyrus and pyramidal cell layer of the hippocampus. Subtypes I and III showed moderate expression in granule cells and low expression in the pyramidal cell layer. Distinct expression patterns were also observed in the cortical layers of the middle frontal gyrus and in the entorhinal cortex. In particular, all subtypes exhibited higher levels of expression in cortical layers III, V, and VI compared with layers I and II. All subtypes were expressed in the granular layer of the cerebellum, whereas specific expression of subtypes I, VI, β1, and β2 mRNAs was observed in Purkinje cells. Subtypes I, VI, and β1 mRNAs were expressed, at varying levels, in the pyramidal cells of the deep cerebellar nuclei. These data indicate that, as in rat, human brain sodium channel mRNAs have a distinct regional distribution, with individual cell types expressing different compliments of sodium channels. The differential distribution of sodium channel subtypes suggest that they have distinct roles that are likely to be of paramount importance in maintaining the functional heterogeneity of central nervous system neurons. J. Comp. Neurol. 422:123–139, 2000.
- 23 May 2000
- Published by Wiley in Journal of Comparative Neurology
- Vol. 422 (1) , 123-139
Distribution of voltage-gated sodium channel ?-subunit and ?-subunit mRNAs in human hippocampal formation, cortex, and cerebellum
- 23 May 2000
- Published by Wiley in Journal of Comparative Neurology
- Vol. 422 (1) , 123-139
Distribution of voltage-gated sodium channel ?-subunit and ?-subunit mRNAs in human hippocampal formation, cortex, and cerebellum
- 24 January 2000
- Published by Elsevier in Molecular Brain Research
- Vol. 75 (1) , 96-104
Glial glutamate transporter mRNAs in the genetically absence epilepsy rat from Strasbourg
- 24 January 2000
- Published by Elsevier in Molecular Brain Research
- Vol. 75 (1) , 96-104
Glial glutamate transporter mRNAs in the genetically absence epilepsy rat from Strasbourg
- 1 August 1999
- Published by Elsevier in Molecular Brain Research
- Vol. 71 (2) , 290-303
Visualisation of somatostatin receptor sst3 in the rat central nervous system
- 1 August 1999
- Published by Elsevier in Molecular Brain Research
- Vol. 71 (2) , 290-303
Visualisation of somatostatin receptor sst3 in the rat central nervous system
- 13 October 1998
- Published by Elsevier in Molecular Brain Research
- Vol. 60 (2) , 215-227
Isolation of mouse vomeronasal receptor genes and their co-localization with specific G-protein messenger RNAs
- 13 October 1998
- Published by Elsevier in Molecular Brain Research
- Vol. 60 (2) , 215-227
Isolation of mouse vomeronasal receptor genes and their co-localization with specific G-protein messenger RNAs
- 30 July 1998
- Published by Elsevier in Molecular Brain Research
- Vol. 58 (1-2) , 138-155
Visualisation of non-glycosylated somatostatin receptor two (ngsst2) immunoreactivity in the rat central nervous system
- 30 July 1998
- Published by Elsevier in Molecular Brain Research
- Vol. 58 (1-2) , 138-155
Visualisation of non-glycosylated somatostatin receptor two (ngsst2) immunoreactivity in the rat central nervous system